Prognostic factors for patients with cancer-associated dermatomyositis: a retrospective, multicentre cohort study of 73 patients

被引：0

作者：

Teboul, Alexandre ^{[1
,2
]}

Allenbach, Yves ^{[3
]}

Tubach, Florence ^{[2
]}

Belin, Lisa ^{[2
]}

Cassius, Charles ^{[4
]}

Demortier, Juliette ^{[3
]}

Dossier, Antoine ^{[5
]}

Faucon, Caroline ^{[6
]}

Kasser, Camille ^{[7
]}

Mekinian, Arsene ^{[7
]}

Monseau, Gregoire ^{[8
]}

Fouchard, Maxime ^{[9
]}

Chambrelan, Estel ^{[9
]}

Viguier, Manuelle ^{[10
]}

Kluger, Nicolas ^{[11
]}

Mahevas, Thibault ^{[4
]}

Bergeret, Blanche ^{[12
]}

Bachmeyer, Claude ^{[13
]}

Lenormand, Cedric ^{[14
]}

Hotz, Claire ^{[15
]}

Diaz, Emmanuelle ^{[16
]}

Cordel, Nadege ^{[17
]}

Benveniste, Olivier ^{[3
]}

Bessis, Didier ^{[18
]}

Bouaziz, Jean-David ^{[4
]}

Chasset, Francois ^{[1
]}

机构：

[1] Sorbonne Univ, Hop Tenon, Assistance Publ Hop Paris, Serv Dermatol & Allergol,Fac Med, 4 Rue Chine, F-75020 Paris, France

[2] Sorbonne Univ, Hop Pitie Salpetriere, Assistance Publ Hop Paris, Dept Sante Publ,Inst Pierre Louis Epidemiol & Sant, Paris, France

[3] Univ Paris Est Creteil, Grp Hosp Pitie Salpetriere, Assistance Publ Hop Paris, Ctr Rech Myol U974,Ctr Reference Myopathies Inflam, Paris, France

[4] Univ Paris Cite, Assistance Publ Hop Paris, Assistance Publ Hop Paris, Serv Dermatol,Fac Med, Paris, France

[5] Hop Bichat Claude Bernard, Assistance Publ Hop Paris, Serv Med Interne, Paris, France

[6] Hop Bichat Claude Bernard, Assistance Publ Hop Paris, Serv Dermatol, Paris, France

[7] Hop St Antoine, Assistance Publ Hop Paris, Dept Internal Med, Inflammat Immunopathol Biotherapy Dept DHU i2B, Paris, France

[8] Ctr Hosp Perigueux, Perigueux, France

[9] CHU Rennes, Serv Dermatol, F-35000 Rennes, France

[10] Univ Reims, Hop Robert Debre, Dept Dermatol Venereol, EA7509,IRMAIC, Reims, France

[11] Univ Helsinki, Helsinki Univ Hosp, Dept Dermatol Allergol & Venereol, Helsinki, Finland

[12] CHU Nimes, Serv Dermatol, Nimes, France

[13] Sorbonne Univ, Serv Anat & Cytol Pathol, Hop Tenon, Ctr Reference Malad Autoinflammatoires & Amyloses, Paris, France

[14] Hop Univ Strasbourg, Serv Dermatol, Hop Civil, Strasbourg, France

[15] Hop Jacques Puel, Ctr Hosp Rodez, Ctr Hosp Rodez, Rodez, France

[16] Hop Henri Mondor, Assistance Publ Hop Paris, Serv Dermatol, Creteil, France

[17] Guadeloupe Univ Hosp, Dept Dermatol & Clin Immunol, Point A Pitre, Guadeloupe, France

[18] Univ Montpellier, Ctr Hosp Univ Montpellier, Montpellier, France

来源：

RHEUMATOLOGY | 2025年 / 64卷 / 05期

关键词：

paraneoplastic; DM; cancer; cancer-associated DM; immunology; prognosis; immunosuppressants; oncology; POLYMYOSITIS; ADULT; CLASSIFICATION; MALIGNANCY; GUIDELINES; MYOSITIS; RISK;

D O I：

10.1093/rheumatology/keae629

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objectives: To investigate factors associated with DM complete clinical response and overall survival with a focus on the use of immunosuppressive therapies in patients with cancer-associated DM. Methods: We performed a multicentre, retrospective cohort study. Multivariable survival analyses used a Cox model with time-dependent covariates and adjustments with inverse probability censoring weighting. Results: We included 73 patients with cancer-associated DM. Median follow-up was 3.92 years. Overall, 40 (54.8%) patients achieved cancer remission, with DM complete clinical response in 28/40 (70.0%). DM complete clinical response was associated with cancer remission (hazard ratio [HR] 2.46, 95% CI [1.13-5.32]) and younger age (HR 0.68, 95% CI [0.49-0.95]). Risk of mortality was associated with sustained cancer activity (HR 12.93, 95% CI [2.42-69.25]), male sex (HR 2.82, 95% CI [1.19-6.70]), and older age (HR 1.86, 95% CI [1.26-2.79]) but not sustained DM activity (HR 0.40, 95% CI [0.13-1.26]). Oral corticosteroid use was a protective factor only on univariate analysis (HR 0.18, 95% CI [0.08-0.42]). Conclusion: This study provides strong evidence of a significant association between the evolutions of DM and cancer, both in terms of overall survival and DM complete clinical response. Immunosuppressive treatments for DM were not significantly associated with mortality. Trial registration: ClinicalTrials.gov, NCT04637672.

引用

页码：2970 / 2978

页数：9

共 26 条

[1] 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative [J].